Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma
J. Alberto Nakauma-González(Erasmus MC Cancer Institute), Joost L. Boormans(Erasmus MC), Job van Riet(Erasmus MC Cancer Institute), Sjoukje F. Oosting(University Medical Center Groningen), Michiel S. van der Heijden(Zorginstituut Nederland), Niven Mehra(Royal Marsden NHS Foundation Trust), Ellen C. Zwarthoff(Erasmus MC), Ronald de Wit(Erasmus MC Cancer Institute), L. Lucia Rijstenberg(Erasmus MC Cancer Institute), Hans M. Westgeest(Amphia Ziekenhuis), Edwin Cuppen(University Medical Center Utrecht), Martijn P. Lolkema(National Institutes of Health), Maud Rijnders(Sint Franciscus Gasthuis), Sandra van Wilpe(Radboud University Medical Center), Harmen J.G. van de Werken(Erasmus MC), Jens Voortman(Vrije Universiteit Amsterdam), Astrid A.M. van der Veldt(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)
Cited by 46
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Organoid Models of Human and Mouse Ductal Pancreatic Cancer
|Cell|2014|2.2k